This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration And Expanded Access To Healthcare Attracting Big Pharma Investment

5.1.2 Biotech 38

5.1.3 Over-the-Counter Drugs 42

5.1.4 Prescription Drugs 42

5.1.5 Herbal Medicines 43

5.2 Market Segmentation 44

6 Indian Pharmaceutical Market Outlook – Market Analysis by Therapeutic Categories 46

6.1 Market Share of Leading Therapeutic Segment 46

6.2 Anti-Infectives 47

6.2.1 Market Size 47

6.2.2 Key Brands and Players 48

6.2.3 Recent Developments 48

6.2.4 Outlook 48

6.3 Cardiovascular System 49

6.3.1 Market Size 49

6.3.2 Recent Developments 50

6.3.3 Outlook 50

6.4 Gastrointestinal 51

6.4.1 Market Size 51

6.4.2 Recent Developments 52

6.4.3 Outlook 52

6.5 Diabetes 53

6.5.1 Market Size 53

6.5.2 Recent Developments 54

6.5.3 Outlook 54

6.6 Central Nervous System 55

6.6.1 Market Size 55

6.6.2 Recent Developments 56

6.6.3 Outlook 56

6.7 Respiratory 57

6.7.1 Market Size 57

6.7.2 Recent Developments 58

6.7.3 Outlook 58

6.8 Dermatology 59

6.8.1 Market Size 59

6.8.2 Recent Developments 60

6.8.3 Outlook 60

6.9 Oncology 61

6.9.1 Market Size 61

6.9.2 Recent Developments 62

6.9.3 Outlook 62

7 Indian Pharmaceutical Market Outlook – Key Trends 63

7.1 Rapid Consolidation and Rise of Multinational Corporations in the Indian Pharmaceutical Industry 63

7.1.1 M&A Deals 63

7.1.2 Licensing Deals 65

7.1.3 Partnership Deals 66

7.2 Patent Litigations Favoring Generics 67

7.2.1 Indian Patent Office Revokes Patent for Pfizer's Cancer Drug Sutent (sunitinib) 67

7.2.2 Indian Appeals Body Dismisses Bayer's Plea for Stay on Natco's Generic Nexavar (sorafenib) 67

7.2.3 Delhi High Court Rules in Favor of Cipla in Roche's Tarceva (erlotinib) Patent Lawsuit 67

7.2.4 Indian Supreme Court Asks Novartis to Scale Down Price of Cancer Drug Glivec (imatinib) 67

7.3 Increasing Importance of Rural Marketing in India 68

7.3.1 Case Study - Novartis Arogya Parivar Case Study 68

7.4 Product Localization and India-Specific Pricing 70

7.4.1 Case Study - GlaxoSmithKline, Localized Business Model 70

7.5 Sales Strategies 71

4 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs